Waldenström 巨球蛋白血症

Pratt G, El-Sharkawi D, Kothari J, et al. Diagnosis and management of Waldenström macroglobulinaemia - a British Society for Haematology guideline. Br J Haematol. 2022 Apr;197(2):171-87.全文  摘要

National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: Waldenström macroglobulinemia/lymphoplasmacytic lymphoma. [internet publication].全文

Leblond V, Kastritis E, Advani R, et al. Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia. Blood. 2016 Sep 8;128(10):1321-8.全文  摘要

Kastritis E, Leblond V, Dimopoulos MA, et al. Waldenström's macroglobulinaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018 Oct 1;29 (suppl 4):iv41-50. 摘要

Kapoor P, Ansell SM, Fonseca R, et al. Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines 2016. JAMA Oncol. 2017 Sep 1;3(9):1257-65.全文  摘要

1. International Agency for Research on Cancer; World Health Organization. WHO classification of lymphoid neoplasms, 5th edition. 2022 [internet publication].​全文

2. Campo E, Jaffe ES, Cook JR, et al. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood. 2022 Sep 15;140(11):1229-53.全文  摘要

3. Cesana C, Miqueleiz S, Bernuzzi P, et al. Smouldering Waldenstrom's macroglobulinemia: factors predicting evolution to symptomatic disease. Semin Oncol. 2003;30:231-235. 摘要

4. Merlini G. Waldenstrom's macroglobulinemia - clinical manifestations and prognosis. In: Schechter GP, Hoffman R, Schrier SL, eds. Hematology. Washington, DC: American Society of Hematology; 1999:358-369.

5. Teras LR, DeSantis CE, Cerhan JR, et al. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin. 2016 Nov 12;66(6):443-59.全文  摘要

6. Yin X, Chen L, Fan F, et al. Trends in incidence and mortality of Waldenström Macroglobulinemia: a population-based study. Front Oncol. 2020 Sep 10;10:1712.全文  摘要

7. Wang H, Chen Y, Li F, et al. Temporal and geographic variations of Waldenstrom macroglobulinemia incidence: a large population-based study. Cancer. 2012 Aug 1;118(15):3793-800.全文  摘要

8. Groves FD, Travis LB, Devesa SS, et al. Waldenstrom's macroglobulinemia: incidence patterns in the United States, 1988-1994. Cancer. 1998;82:1078-1081. 摘要

9. Herrinton LJ, Weiss NS. Incidence of Waldenstrom's macroglobulinemia. Blood. 1993;82:3148-3150.全文  摘要

10. Castillo JJ, Olszewski AJ, Kanan S, et al. Overall survival and competing risks of death in patients with Waldenström macroglobulinaemia: an analysis of the Surveillance, Epidemiology and End Results database. Br J Haematol. 2015 Apr;169(1):81-9.全文  摘要

11. Phekoo KJ, Jack RH, Davies E, et al. The incidence and survival of Waldenstrom's macroglobulinaemia in South East England. Leuk Res. 2008;32:55-59. 摘要

12. Owen RG, Pratt G, Auer RL, et al. Guidelines on the diagnosis and management of Waldenström macroglobulinaemia. Br J Haematol. 2014 May;165(3):316-33.全文  摘要

13. Wan Y, Cheng Y, Liu Y, et al. Screening and identification of a novel FHL2 mutation by whole exome sequencing in twins with familial Waldenström macroglobulinemia. Cancer. 2021 Jun 15;127(12):2039-48.全文  摘要

14. Kyle RA, Therneau TM, Rajkumar SV, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med. 2002 Feb 21;346(8):564-9.全文  摘要

15. Treon SP, Hunter ZR, Aggarwal A, et al. Characterization of familial Waldenström's macroglobulinemia. Ann Oncol. 2006;17:488-494.全文  摘要

16. Ogmundsdottir HM, Einarsdottir HK, Steingrimsdottir H, et al. Familial predisposition to monoclonal gammopathy of unknown significance, Waldenstrom's macroglobulinemia, and multiple myeloma. Clin Lymphoma Myeloma. 2009;9:27-29. 摘要

17. McMaster ML. Familial Waldenstrom's macroglobulinemia. Semin Oncol. 2003;30:146-152. 摘要

18. Kristinsson SY, Koshiol J, Goldin LR, et al. Genetics- and immune-related factors in the pathogenesis of lymphoplasmacytic lymphoma/Waldenstrom's macroglobulinemia. Clin Lymphoma Myeloma. 2009;9:23-26. 摘要

19. Treon SP, Xu L, Yang G, et al. MYD88 L265P somatic mutation in Waldenström's macroglobulinemia. N Engl J Med. 2012 Aug 30;367(9):826-33.全文  摘要

20. Treon SP, Tripsas CK, Meid K, et al. Ibrutinib in previously treated Waldenström's macroglobulinemia. N Engl J Med. 2015 Apr 9;372(15):1430-40.全文  摘要

21. Fulciniti M, Amodio N, Bandi RL, et al. MYD88-independent growth and survival effects of Sp1 transactivation in Waldenstrom macroglobulinemia. Blood. 2014;123:2673-2681. 摘要

22. Roccaro AM, Sacco A, Jimenez C, et al. C1013G/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma. Blood. 2014;123:4120-4131. 摘要

23. Xu L, Hunter ZR, Tsakmaklis N, et al. Clonal architecture of CXCR4 WHIM-like mutations in Waldenström macroglobulinaemia. Br J Haematol. 2016 Mar;172(5):735-44.全文  摘要

24. Hunter ZR, Xu L, Yang G, et al. The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis. Blood. 2014;123:1637-1646.全文  摘要

25. Treon SP, Hunter ZR. A new era for Waldenstrom macroglobulinemia: MYD88 L265P. Blood. 2013;121:4434-4436.全文  摘要

26. Treon SP, Gustine J, Xu L, et al. MYD88 wild-type Waldenstrom macroglobulinaemia: differential diagnosis, risk of histological transformation, and overall survival. Br J Haematol. 2018 Feb;180(3):374-80.全文  摘要

27. Sahota SS, Forconi F, Ottensmeier CH, et al. Origins of the malignant clone in typical Waldenstrom's macroglobulinemia. Semin Oncol. 2003;30:136-141. 摘要

28. Roccaro AM, Sacco A, Shi J, et al. Exome sequencing reveals recurrent germ line variants in patients with familial Waldenström macroglobulinemia. Blood. 2016 May 26;127(21):2598-606.全文  摘要

29. McMaster ML, Berndt SI, Zhang J, et al. Two high-risk susceptibility loci at 6p25.3 and 14q32.13 for Waldenström macroglobulinemia. Nat Commun. 2018 Oct 10;9(1):4182.全文  摘要

30. Giordano TP, Henderson L, Landgren O, et al. Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus. JAMA. 2007;297:2010-2017. 摘要

31. Leleu X, O'Connor K, Ho AW, et al. Hepatitis C viral infection is not associated with Waldenström's macroglobulinemia. Am J Hematol. 2007;82:83-84.全文  摘要

32. Vijay A, Gertz MA. Waldenström macroglobulinemia. Blood. 2007;109:5096-5103.全文  摘要

33. Weaver A, Rubinstein S, Cornell RF. Hyperviscosity syndrome in paraprotein secreting conditions including Waldenstrom Macroglobulinemia. Front Oncol. 2020 May 19;10:815.全文  摘要

34. Gertz MA. Waldenström macroglobulinemia: 2023 update on diagnosis, risk stratification, and management. Am J Hematol. 2023 Feb;98(2):348-58.全文  摘要

35. Owen RG, Treon SP, Al-Katib A, et al. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's macroglobulinemia. Semin Oncol. 2003;30;110-115. 摘要

36. Pangalis GA, Kyrtsonis MC, Kontopidou FN, et al. Differential diagnosis of Waldenstrom's macroglobulinemia from other low-grade B-cell lymphoproliferative disorders. Semin Oncol. 2003;30:201-205. 摘要

37. Pratt G, El-Sharkawi D, Kothari J, et al. Diagnosis and management of Waldenström macroglobulinaemia - a British Society for Haematology guideline. Br J Haematol. 2022 Apr;197(2):171-87.全文  摘要

38. Leleu X, Moreau AS, Weller E, et al. Serum immunoglobulin free light chain correlates with tumor burden markers in Waldenstrom macroglobulinemia. Leuk Lymphoma. 2008;49:1104-1107. 摘要

39. Kastritis E, Morel P, Duhamel A, et al. A revised international prognostic score system for Waldenström's macroglobulinemia. Leukemia. 2019 Nov;33(11):2654-61. 摘要

40. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: Waldenström macroglobulinemia/lymphoplasmacytic lymphoma. [internet publication].全文

41. Morel P, Duhamel A, Gobbi P, et al. International prognostic scoring system for Waldenström macroglobulinemia. Blood. 2009 Apr 30;113(18):4163-70.全文  摘要

42. Treon SP. How I treat Waldenström macroglobulinemia. Blood. 2015 Aug 6;126(6):721-32.全文  摘要

43. Owen RG, Barrans SL, Richards SJ, et al. Waldenström macroglobulinemia: development of diagnostic criteria and identification of prognostic factors. Am J Clin Pathol. 2001 Sep;116(3):420-8.全文  摘要

44. Giné E, Rovira J, Martinez-Trillos, et al. Initial features and outcome are similar in patients with lymphoplasmacytic lymphoma regardless they meet or not criteria of Waldenström macroglobulinemia. Blood (ASH Annual Meeting Abstracts). 2011;118:3677.全文

45. Treon SP, Xu L, Guerrera ML, et al. Genomic landscape of Waldenström macroglobulinemia and its impact on treatment strategies. J Clin Oncol. 2020 Apr 10;38(11):1198-208.全文  摘要

46. Banwait R, O'Regan K, Campigotto F, et al. The role of 18F-FDG PET/CT imaging in Waldenstrom macroglobulinemia. Am J Hematol. 2011;86:567-572. 摘要

47. Castillo JJ, Treon SP. Initial evaluation of the patient with Waldenström Macroglobulinemia. Hematol Oncol Clin North Am. 2018 Oct;32(5):811-820.全文  摘要

48. Vitolo U, Ferreri AJ, Montoto S. Lymphoplasmacytic lymphoma-Waldenström's macroglobulinemia. Crit Rev Oncol Hematol. 2008;67:172-185. 摘要

49. Gertz MA, Merlini G, Treon SP. Amyloidosis and Waldenström's macroglobulinemia. Hematology Am Soc Hematol Educ Program. 2004:257-282.全文  摘要

50. Berentsen S, Beiske K, Tjønnfjord GE, et al. Primary chronic cold agglutinin disease: an update on pathogenesis, clinical features and therapy. Hematology. 2007;12:361-370.全文  摘要

51. Leblond V, Kastritis E, Advani R, et al. Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia. Blood. 2016 Sep 8;128(10):1321-8.全文  摘要

52. Kastritis E, Leblond V, Dimopoulos MA, et al. Waldenström's macroglobulinaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018 Oct 1;29 (suppl 4):iv41-50. 摘要

53. Dimopoulos MA, Kastritis E. How I treat Waldenström macroglobulinemia. Blood. 2019 Dec 5;134(23):2022-35.全文  摘要

54. Buske C, Sadullah S, Kastritis E, et al. Treatment and outcome patterns in European patients with Waldenström's macroglobulinaemia: a large, observational, retrospective chart review. Lancet Haematol. 2018 Jul;5(7):e299-309. 摘要

55. Castillo JJ, Advani RH, Branagan AR, et al. Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia. Lancet Haematol. 2020 Nov;7(11):e827-e837.全文  摘要

56. Ghobrial IM, Fonseca R, Greipp PR, et al. Initial immunoglobulin M 'flare' after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia: an Eastern Cooperative Oncology Group Study. Cancer. 2004 Dec 1;101(11):2593-8.全文  摘要

57. Rummel MJ, Niederle N, Maschmeyer G, et al; Study Group Indolent Lymphomas. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381:1203-1210. 摘要

58. Paludo J, Abeykoon JP, Shreders A, et al. Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia. Ann Hematol. 2018 Aug;97(8):1417-25. 摘要

59. Laribi K, Poulain S, Willems L, et al. Bendamustine plus rituximab in newly-diagnosed Waldenström macroglobulinaemia patients: a study on behalf of the French Innovative Leukaemia Organization (FILO). Br J Haematol. 2019 Jul;186(1):146-9.全文  摘要

60. Fung M, Jacobsen E, Freedman A, et al. Increased risk of infectious complications in older patients with indolent non-Hodgkin lymphoma exposed to bendamustine. Clin Infect Dis. 2019 Jan 7;68(2):247-55.全文  摘要

61. Gavriatopoulou M, García-Sanz R, Kastritis E, et al. BDR in newly diagnosed patients with WM: final analysis of a phase 2 study after a minimum follow-up of 6 years. Blood. 2017 Jan 26;129(4):456-9.全文  摘要

62. Treon SP, Ioakimidis L, Soumerai JD, et al. Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180. J Clin Oncol. 2009;27:3830-3835. 摘要

63. Dimopoulos MA, Chen C, Kastritis E, et al. Bortezomib as a treatment option in patients with Waldenström macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2010 Apr;10(2):110-7. 摘要

64. Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, et al. Primary treatment of Waldenström macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide. J Clin Oncol. 2007;25:3344-9.全文  摘要

65. Kastritis E, Gavriatopoulou M, Kyrtsonis MC, et al. Dexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenström macroglobulinemia: final analysis of a phase 2 study. Blood. 2015 Sep 10;126(11):1392-4.全文  摘要

66. Ghobrial IM, Xie W, Padmanabhan S, et al. Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenström macroglobulinemia. Am J Hematol. 2010 Sep;85(9):670-4.全文  摘要

67. Cappuccio JM, Ghobrial IM, Castillo JJ, et al. Long-term follow-up of exceptional responders on the phase II trial of weekly bortezomib and rituximab in untreated and relapsed patients with Waldenstrom's macroglobulinemia. J Clin Oncol. 2016 May 20;34(15 suppl):8065.全文

68. Treon SP, Gustine J, Meid K, et al. Ibrutinib monotherapy in symptomatic, treatment-naïve patients with Waldenström macroglobulinemia. J Clin Oncol. 2018 Sep 20;36(27):2755-61.全文  摘要

69. Dimopoulos MA, Tedeschi A, Trotman J, et al. Phase 3 trial of ibrutinib plus rituximab in Waldenström's macroglobulinemia. N Engl J Med. 2018 Jun 21;378(25):2399-410.全文  摘要

70. Buske C, Tedeschi A, Trotman J, et al. Ibrutinib plus rituximab versus placebo plus rituximab for Waldenström's macroglobulinemia: final analysis from the randomized Phase III iNNOVATE study. J Clin Oncol. 2022 Jan 1;40(1):52-62.全文  摘要

71. Tam CS, Opat S, D'Sa S, et al. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study. Blood. 2020 Oct 29;136(18):2038-50.全文  摘要

72. Dimopoulos MA, Opat S, D'Sa S, et al. Zanubrutinib Versus Ibrutinib in symptomatic Waldenström macroglobulinemia: final analysis from the randomized phase III ASPEN study. J Clin Oncol. 2023 Nov 20;41(33):5099-106.全文  摘要

73. Caldeira D, Alves D, Costa J, et al. Ibrutinib increases the risk of hypertension and atrial fibrillation: systematic review and meta-analysis. PLoS One. 2019 Feb 20;14(2):e0211228.全文  摘要

74. Tang CPS, Lip GYH, McCormack T, et al. Management of cardiovascular complications of bruton tyrosine kinase inhibitors. Br J Haematol. 2022 Jan;196(1):70-78.全文

75. Jain P, Thompson PA, Keating M, et al. Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinib. Cancer. 2017 Jun 15;123(12):2268-73.全文  摘要

76. Leong DP, Caron F, Hillis C, et al. The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis. Blood. 2016 Jul 7;128(1):138-40.全文

77. Lee DH, Hawk F, Seok K, et al. Association between ibrutinib treatment and hypertension. Heart. 2022 Mar;108(6):445-50.全文  摘要

78. Stone MJ, Bogen SA. Role of plasmapheresis in Waldenström's macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2013 Apr;13(2):238-40. 摘要

79. Gertz MA. Waldenstrom macroglobulinemia: tailoring therapy for the individual. J Clin Oncol. 2022 Aug 10;40(23):2600-8.全文  摘要

80. Kapoor P, Ansell SM, Fonseca R, et al. Diagnosis and management of Waldenström macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines 2016. JAMA Oncol. 2017 Sep 1;3(9):1257-65.全文  摘要

81. Dimopoulos MA, Kastritis E, Owen RG, et al. Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus. Blood. 2014 Aug 28;124(9):1404-11.全文  摘要

82. Owen RG, Kyle RA, Stone MJ, et al. Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop. Br J Haematol. 2013 Jan;160(2):171-6.全文  摘要

83. Treon SP, Hanzis C, Manning RJ, et al. Maintenance rituximab is associated with improved clinical outcome in rituximab naïve patients with Waldenstrom macroglobulinaemia who respond to a rituximab-containing regimen. Br J Haematol. 2011;154:357-362. 摘要

84. Leblond V, Johnson S, Chevret S, et al. Results of a randomized trial of chlorambucil versus fludarabine for patients with untreated Waldenström macroglobulinemia, marginal zone lymphoma, or lymphoplasmacytic lymphoma. J Clin Oncol. 2013 Jan 20;31(3):301-7.全文  摘要

85. Treon SP, Meid K, Gustine J, et al. Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenström Macroglobulinemia. J Clin Oncol. 2021 Feb 20;39(6):565-575.全文  摘要

86. Owen RG, McCarthy H, Rule S, et al. Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 study. Lancet Haematol. 2020 Feb;7(2):e112-21. 摘要

87. Treon S, Hunter Z, Matous J, et al. Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinaemia: results of WMCTG trial 03-248. Clin Cancer Res. 2007;13:3320-3325.全文  摘要

88. Chen CI, Kouroukis CT, White D, et al. Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007 Apr 20;25(12):1570-5.全文  摘要

89. Dimopoulos MA, Trotman J, Tedeschi A, et al. Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial. Lancet Oncol. 2017 Feb;18(2):241-50. 摘要

90. Treon SP, Hanzis C, Tripsas C, et al. Bendamustine therapy in patients with relapsed or refractory Waldenström's macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2011 Feb;11(1):133-5. 摘要

91. Ghobrial IM, Hong F, Padmanabhan S, et al. Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia. J Clin Oncol. 2010 Mar 10;28(8):1422-8.全文  摘要

92. Treon SP, Branagan AR, Ioakimidis L, et al. Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia. Blood. 2009 Apr 16;113(16):3673-8.全文  摘要

93. Tedeschi A, Benevolo G, Varettoni M, et al. Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia: an effective but myelosuppressive regimen to be offered to patients with advanced disease. Cancer. 2012 Jan 15;118(2):434-43.全文  摘要

94. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: hematopoietic cell transplantation (HCT) [internet publication].全文

95. Kyriakou C, Canals C, Sibon D, et al. High-dose therapy and autologous stem-cell transplantation in Waldenström macroglobulinemia: the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2010;28:2227-2232. 摘要

96. Kyriakou C, Canals C, Taghipour G, et al. Autologous stem cell transplantation (ASCT) for patients with Waldenstrom's macroglobulinemia: an analysis of 201 cases from the European Bone Marrow Transplant Registry (EBMT). Haematologica. 2007;92(suppl):PO-1228(abstr).

97. Kyriakou C, Canals C, Taghipour G, et al. Allogeneic stem cell transplantation (ALLO-SCT) in Waldenstrom macroglobulinemia (WM): an analysis of 106 cases from the European Bone Marrow Registry (EBMT). Haematologica. 2007;92(suppl):WM3.9(abstr).

98. Kyriakou C, Canals C, Cornelissen JJ, et al. Allogeneic stem-cell transplantation in patients with Waldenström macroglobulinemia: report from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2010 Nov 20;28(33):4926-34.全文  摘要

99. Cornell RF, Bachanova V, D'Souza A, et al. Allogeneic transplantation for relapsed Waldenström macroglobulinemia and lymphoplasmacytic lymphoma. Biol Blood Marrow Transplant. 2017 Jan;23(1):60-6.全文  摘要

100. Leong DP, Caron F, Hillis C, et al. The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis. Blood. 2016 Jul 7;128(1):138-40.全文  摘要

101. Treon SP, Tripsas CK, Meid K, et al. Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenström's macroglobulinemia. Blood. 2014;124:503-510.全文  摘要

102. Rosenthal A, Luthi J, Belohlavek M, et al. Carfilzomib and the cardiorenal system in myeloma: an endothelial effect? Blood Cancer J. 2016 Jan 15;6(1):e384.全文  摘要

103. Castillo JJ, Meid K, Gustine JN, et al. Prospective clinical trial of ixazomib, dexamethasone, and rituximab as primary therapy in Waldenström macroglobulinemia. Clin Cancer Res. 2018 Jul 15;24(14):3247-52.全文  摘要

104. Castillo JJ, Gustine J, Meid K, et al. Multicenter prospective phase II study of venetoclax in patients with previously treated Waldenstrom macroglobulinemia. Blood. 2018 Nov 29;132(suppl 1):2888.全文

105. Paulus A, Manna A, Akhtar S, et al. Targeting CD38 with daratumumab is lethal to Waldenström macroglobulinaemia cells. Br J Haematol. 2018 Oct;183(2):196-211.全文  摘要

106. Vidal-Crespo A, Matas-Céspedes A, Rodriguez V, et al. Daratumumab displays in vitro and in vivo anti-tumor activity in models of B-cell non-Hodgkin lymphoma and improves responses to standard chemo-immunotherapy regimens. Haematologica. 2020 Apr;105(4):1032-41.全文  摘要

107. Ghobrial IM, Witzig TE, Gertz M, et al. Long-term results of the phase II trial of the oral mTOR inhibitor everolimus (RAD001) in relapsed or refractory Waldenstrom macroglobulinemia. Am J Hematol. 2014;89:237-242. 摘要

108. Treon SP, Meid K, Tripsas C, et al. Prospective, multicenter clinical trial of everolimus as primary therapy in Waldenstrom macroglobulinemia (WMCTG 09-214). Clin Cancer Res. 2017 May 15;23(10):2400-4.全文  摘要

109. Ghobrial IM, Roccaro A, Hong F, et al. Clinical and translational studies of a phase II trial of the novel oral Akt inhibitor perifosine in relapsed or relapsed/refractory Waldenström's macroglobulinemia. Clin Cancer Res. 2010;16:1033-1041.全文  摘要

110. Ghobrial IM, Leleu X, Azab AK, et al. Novel therapeutic agents in Waldenstrom's macroglobulinaemia. Clin Lymphoma Myeloma. 2009;9:84-86. 摘要

111. Ghobrial IM, Campigotto F, Murphy TJ, et al. Results of a phase 2 trial of the single-agent histone deacetylase inhibitor panobinostat in patients with relapsed/refractory Waldenström macroglobulinemia. Blood. 2013 Feb 21;121(8):1296-303.全文  摘要

112. Furman RR, Eradat H, DiRienzo CG, et al. A phase II trial of ofatumumab in subjects with Waldenstrom's macroglobulinemia. Blood. 2011;118:3701.全文

113. Herth I, Hensel M, Rieger M, et al. Pentostatin, cyclophosphamide and rituximab is a safe and effective treatment in patients with Waldenström's macroglobulinemia. Leuk Lymphoma. Leuk Lymphoma. 2015;56:97-102. 摘要

114. Mato AR, Shah NN, Jurczak W, et al. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. Lancet. 2021 Mar 6;397(10277):892-901. 摘要

115. Randen U, Trøen G, Tierens A, et al. Primary cold agglutinin-associated lymphoproliferative disease: a B-cell lymphoma of the bone marrow distinct from lymphoplasmacytic lymphoma. Haematologica. 2014 Mar;99(3):497-504.全文  摘要

116. Schollkopf C, Kjeldsen L, Bjerrum OW, et al. Rituximab in chronic cold agglutinin disease: a prospective study of 20 patients. Leuk Lymphoma. 2006;47:253-260. 摘要

117. Leleu X, Soumerai J, Roccaro A, et al. Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogs. J Clin Oncol. 2009;27:250-255. 摘要

118. Kyle RA, Greipp PR, Gertz MA, et al. Waldenström's macroglobulinemia: a prospective study comparing daily with intermittent oral chlorambucil. Br J Haematol. 2000;108:737-742.全文  摘要

119. Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, et al. Treatment of relapsed or refractory Waldenström's macroglobulinaemia with bortezomib. Haematologica. 2005;90:1655-1658.全文  摘要

120. Baldini L, Nobile-Orazio E, Guffanti A, et al. Peripheral neuropathy in IgM monoclonal gammopathy and Waldenstrom's macroglobulinemia: a frequent complication in elderly males with low MAG-reactive serum monoclonal component. Am J Hematol. 1994;45:25-31. 摘要

121. Mazurier C, Parquet-Gernez A, Descamps J, et al. Acquired von Willebrand's syndrome in the course of Waldenström's disease. Thromb Haemost. 1980 Dec 19;44(3):115-8. 摘要

122. Hivert B, Caron C, Petit S, et al. Clinical and prognostic implications of low or high level of von Willebrand factor in patients with Waldenstrom macroglobulinemia. Blood. 2012 Oct 18;120(16):3214-21.全文  摘要

123. Castillo JJ, Gustine JN, Meid K, et al. Low levels of von Willebrand markers associate with high serum IgM levels and improve with response to therapy, in patients with Waldenström macroglobulinaemia. Br J Haematol. 2019 Mar;184(6):1011-4.全文

124. Sidana S, Larson DP, Greipp PT, et al. IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological features. Leukemia. 2020 May;34(5):1373-82.全文  摘要

125. Kumar S, Dispenzieri A, Lacy MQ, et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol. 2012 Mar 20;30(9):989-95.全文  摘要